CN112603942A - 一种用于治疗犊牛胃肠道疾病的藏药复方及其制备方法和应用 - Google Patents
一种用于治疗犊牛胃肠道疾病的藏药复方及其制备方法和应用 Download PDFInfo
- Publication number
- CN112603942A CN112603942A CN202110042083.0A CN202110042083A CN112603942A CN 112603942 A CN112603942 A CN 112603942A CN 202110042083 A CN202110042083 A CN 202110042083A CN 112603942 A CN112603942 A CN 112603942A
- Authority
- CN
- China
- Prior art keywords
- parts
- medicine compound
- tibetan medicine
- mice
- myrobalan
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 87
- 150000001875 compounds Chemical class 0.000 title claims abstract description 52
- 244000309466 calf Species 0.000 title claims abstract description 49
- 238000002360 preparation method Methods 0.000 title claims abstract description 19
- 208000018522 Gastrointestinal disease Diseases 0.000 title claims description 13
- 206010012735 Diarrhoea Diseases 0.000 claims abstract description 54
- 241000218176 Corydalis Species 0.000 claims abstract description 31
- 235000015489 Emblica officinalis Nutrition 0.000 claims abstract description 31
- 244000277583 Terminalia catappa Species 0.000 claims abstract description 31
- 235000011517 Terminalia chebula Nutrition 0.000 claims abstract description 31
- 235000003145 Hippophae rhamnoides Nutrition 0.000 claims abstract description 29
- 241001504825 Dracocephalum tanguticum Species 0.000 claims abstract description 16
- 239000002994 raw material Substances 0.000 claims abstract description 10
- 239000007788 liquid Substances 0.000 claims description 36
- 241000229143 Hippophae Species 0.000 claims description 31
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 23
- 239000000463 material Substances 0.000 claims description 19
- 241001407382 Berberis julianae Species 0.000 claims description 18
- 239000000706 filtrate Substances 0.000 claims description 12
- 206010009887 colitis Diseases 0.000 claims description 10
- 238000005303 weighing Methods 0.000 claims description 10
- 238000001914 filtration Methods 0.000 claims description 8
- 238000007789 sealing Methods 0.000 claims description 6
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 claims description 4
- 238000009924 canning Methods 0.000 claims description 4
- 239000000428 dust Substances 0.000 claims description 4
- 239000004302 potassium sorbate Substances 0.000 claims description 4
- 229940069338 potassium sorbate Drugs 0.000 claims description 4
- 235000010241 potassium sorbate Nutrition 0.000 claims description 4
- 238000002791 soaking Methods 0.000 claims description 4
- 241000531495 Corydalis edulis Species 0.000 claims description 3
- 235000003935 Hippophae Nutrition 0.000 claims description 3
- 238000004140 cleaning Methods 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 31
- 229940079593 drug Drugs 0.000 abstract description 12
- 230000000968 intestinal effect Effects 0.000 abstract description 11
- 241000894006 Bacteria Species 0.000 abstract description 10
- 230000002401 inhibitory effect Effects 0.000 abstract description 8
- 241001465754 Metazoa Species 0.000 abstract description 7
- 230000001737 promoting effect Effects 0.000 abstract description 6
- 238000004519 manufacturing process Methods 0.000 abstract description 4
- 206010030111 Oedema mucosal Diseases 0.000 abstract description 3
- 230000008595 infiltration Effects 0.000 abstract description 3
- 238000001764 infiltration Methods 0.000 abstract description 3
- 210000004969 inflammatory cell Anatomy 0.000 abstract description 3
- 210000002490 intestinal epithelial cell Anatomy 0.000 abstract description 3
- 230000035876 healing Effects 0.000 abstract description 2
- 240000000950 Hippophae rhamnoides Species 0.000 abstract 1
- 206010034133 Pathogen resistance Diseases 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 description 65
- 241000699666 Mus <mouse, genus> Species 0.000 description 17
- 238000012360 testing method Methods 0.000 description 17
- 210000001519 tissue Anatomy 0.000 description 15
- 239000013641 positive control Substances 0.000 description 14
- 210000001072 colon Anatomy 0.000 description 13
- 230000005764 inhibitory process Effects 0.000 description 13
- 241000588724 Escherichia coli Species 0.000 description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 12
- 201000010099 disease Diseases 0.000 description 11
- 230000035945 sensitivity Effects 0.000 description 11
- 238000002474 experimental method Methods 0.000 description 10
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 10
- 239000001963 growth medium Substances 0.000 description 10
- 230000008961 swelling Effects 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- 102000019197 Superoxide Dismutase Human genes 0.000 description 8
- 108010012715 Superoxide dismutase Proteins 0.000 description 8
- 230000000202 analgesic effect Effects 0.000 description 8
- 230000003385 bacteriostatic effect Effects 0.000 description 8
- 102000003896 Myeloperoxidases Human genes 0.000 description 7
- 108090000235 Myeloperoxidases Proteins 0.000 description 7
- 230000001580 bacterial effect Effects 0.000 description 7
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 6
- 208000000114 Pain Threshold Diseases 0.000 description 6
- 229940118019 malondialdehyde Drugs 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 230000037040 pain threshold Effects 0.000 description 6
- TVZRAEYQIKYCPH-UHFFFAOYSA-N 3-(trimethylsilyl)propane-1-sulfonic acid Chemical compound C[Si](C)(C)CCCS(O)(=O)=O TVZRAEYQIKYCPH-UHFFFAOYSA-N 0.000 description 5
- 238000011725 BALB/c mouse Methods 0.000 description 5
- 241000283690 Bos taurus Species 0.000 description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 5
- 206010059866 Drug resistance Diseases 0.000 description 5
- 239000003242 anti bacterial agent Substances 0.000 description 5
- 229940088710 antibiotic agent Drugs 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 230000018109 developmental process Effects 0.000 description 5
- 229960003180 glutathione Drugs 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 4
- 229960000583 acetic acid Drugs 0.000 description 4
- 230000003115 biocidal effect Effects 0.000 description 4
- 208000027503 bloody stool Diseases 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 208000035861 hematochezia Diseases 0.000 description 4
- 229960000905 indomethacin Drugs 0.000 description 4
- 229920001817 Agar Polymers 0.000 description 3
- 206010014025 Ear swelling Diseases 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 239000008272 agar Substances 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 238000009395 breeding Methods 0.000 description 3
- 230000001488 breeding effect Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- -1 compound diphenoxylate Chemical class 0.000 description 3
- 229960004192 diphenoxylate Drugs 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 239000012362 glacial acetic acid Substances 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 210000004347 intestinal mucosa Anatomy 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 230000005180 public health Effects 0.000 description 3
- 210000001187 pylorus Anatomy 0.000 description 3
- 210000000813 small intestine Anatomy 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- 235000006693 Cassia laevigata Nutrition 0.000 description 2
- 206010009900 Colitis ulcerative Diseases 0.000 description 2
- 206010021518 Impaired gastric emptying Diseases 0.000 description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 2
- UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 description 2
- 241000522641 Senna Species 0.000 description 2
- 201000006704 Ulcerative Colitis Diseases 0.000 description 2
- 210000000683 abdominal cavity Anatomy 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000001142 anti-diarrhea Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 238000010227 cup method (microbiological evaluation) Methods 0.000 description 2
- 235000013365 dairy product Nutrition 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000003467 diminishing effect Effects 0.000 description 2
- 230000009266 disease activity Effects 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 208000028774 intestinal disease Diseases 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 208000002551 irritable bowel syndrome Diseases 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000003340 mental effect Effects 0.000 description 2
- 210000003739 neck Anatomy 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- 229960001180 norfloxacin Drugs 0.000 description 2
- OGJPXUAPXNRGGI-UHFFFAOYSA-N norfloxacin Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 OGJPXUAPXNRGGI-UHFFFAOYSA-N 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 229940124513 senna glycoside Drugs 0.000 description 2
- 229940076742 senna leaves Drugs 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 description 2
- 229960001940 sulfasalazine Drugs 0.000 description 2
- NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- 239000008096 xylene Substances 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 238000009631 Broth culture Methods 0.000 description 1
- 240000006740 Cichorium endivia Species 0.000 description 1
- 235000018536 Cichorium endivia Nutrition 0.000 description 1
- 241001537325 Corydalis ochotensis Species 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 208000019505 Deglutition disease Diseases 0.000 description 1
- 241001529849 Dracocephalum Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 206010016100 Faeces discoloured Diseases 0.000 description 1
- 206010016952 Food poisoning Diseases 0.000 description 1
- 208000019331 Foodborne disease Diseases 0.000 description 1
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- 102000006587 Glutathione peroxidase Human genes 0.000 description 1
- 108700016172 Glutathione peroxidases Proteins 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 208000015580 Increased body weight Diseases 0.000 description 1
- 244000062241 Kaempferia galanga Species 0.000 description 1
- 235000013421 Kaempferia galanga Nutrition 0.000 description 1
- ZRVUJXDFFKFLMG-UHFFFAOYSA-N Meloxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=NC=C(C)S1 ZRVUJXDFFKFLMG-UHFFFAOYSA-N 0.000 description 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
- 208000014174 Oesophageal disease Diseases 0.000 description 1
- 239000004100 Oxytetracycline Substances 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 241000972672 Phellodendron Species 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 244000294611 Punica granatum Species 0.000 description 1
- 235000014360 Punica granatum Nutrition 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010067171 Regurgitation Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003212 astringent agent Substances 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229940000425 combination drug Drugs 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 229960001259 diclofenac Drugs 0.000 description 1
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 239000003640 drug residue Substances 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 208000030304 gastrointestinal bleeding Diseases 0.000 description 1
- 208000001288 gastroparesis Diseases 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002439 hemostatic effect Effects 0.000 description 1
- 244000144980 herd Species 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 208000003243 intestinal obstruction Diseases 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 230000001678 irradiating effect Effects 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 230000006651 lactation Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 229960001929 meloxicam Drugs 0.000 description 1
- 210000000713 mesentery Anatomy 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 229960002009 naproxen Drugs 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
- 235000003170 nutritional factors Nutrition 0.000 description 1
- 229960000625 oxytetracycline Drugs 0.000 description 1
- IWVCMVBTMGNXQD-PXOLEDIWSA-N oxytetracycline Chemical compound C1=CC=C2[C@](O)(C)[C@H]3[C@H](O)[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-PXOLEDIWSA-N 0.000 description 1
- 235000019366 oxytetracycline Nutrition 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229910052573 porcelain Inorganic materials 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001141 propulsive effect Effects 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 231100000272 reduced body weight Toxicity 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- IWVCMVBTMGNXQD-UHFFFAOYSA-N terramycin dehydrate Natural products C1=CC=C2C(O)(C)C3C(O)C4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 239000000273 veterinary drug Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000013585 weight reducing agent Substances 0.000 description 1
- 206010048282 zoonosis Diseases 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/29—Berberidaceae (Barberry family), e.g. barberry, cohosh or mayapple
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/66—Papaveraceae (Poppy family), e.g. bloodroot
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明涉及一种用于治疗犊牛腹泻的藏药复方及其制备方法,涉及医药技术领域。所述的藏药复方由下述重量配比的原料制成:三颗针1~3份、沙棘1~4份、诃子5份、甘青青兰2份、矮紫堇2份。本发明的藏药复方具有抑菌止泻镇痛功效,同时还具备降低肠推进率的作用,抑制肠上皮细胞脱落,降低粘膜水肿、减少炎症细胞浸润,促进腹泻快速愈合,不易产生细菌耐药性,不影响动物生产性能。
Description
技术领域
本发明涉及医药制剂技术领域,尤其涉及一种用于治疗犊牛胃肠道疾病的藏药复方及其制备方法和应用。
背景技术
胃肠道疾病涵盖食管、胃、小肠、结肠和直肠等疾病,常见的主要症状包括节律性、周期性上腹痛、腹泻、饥饿性腹痛、反酸、发烧、黑便血便、消化道出血和肠梗阻等。胃肠道疾病是人类最常见的疾病之一,其中最常见的包括吞咽障碍、胃溃疡、消化性溃疡、胃轻瘫、胃排空延迟、肠易激综合征(IBS)和炎症性肠病(IBD)。腹泻属于肠道疾病的一种症状,多由疾病因素导致,且以肠道疾病为多见,其他常见的有急性食物中毒、全身性感染等,细菌感染为常见原因之一。犊牛腹泻严重影响牛养殖业的健康发展。犊牛腹泻是细菌、病毒、寄生虫等病原微生物感染或营养因素、环境、管理等多种因素造成。近几年来,随着奶牛养殖业规模扩大,犊牛腹泻的发病率呈上升趋势,犊牛腹泻严重影响犊牛早期的生长发育和后期生产性能的发挥。犊牛腹泻不仅直接影响犊牛的生长发育,而且因死亡率高影响牛群的更新和奶牛养殖业的良性发展。同时,引起犊牛腹泻的某些原虫是重要的人畜共患病原微生物,会严重威胁地区的公共卫生安全。因此,有效控制犊牛腹泻刻不容缓。
犊牛腹泻一般发生在1月内的犊牛。其主要临床表征喂腹泻、消化不良,是一种胃肠消化类的疾病。犊牛腹泻全年可以发生、尤其是气温周边更易多发,当犊牛处于哺乳期是,更易发病,其约占整个犊牛腹泻发病率的80%,即使患过犊牛腹泻的犊牛、在其生长过程同比其他犊牛还容易感染呼吸道方面的疾病。因此该病对犊牛生长发育乃至成活都会产生巨大影响。
犊牛腹泻病因比较复杂,难以对症下药,具有较高的死亡率,有新生犊牛“杀手”之称。其一旦发病,多以庆大霉素、诺氟沙星、土霉素、氟哌酸等抗生素对其采取治疗,但其发病原因不一定是细菌引起,因此针对性不强,容易出现细菌的耐药性以及相应的畜产品药残过多等问题出现,具有严重的公共卫生安全等问题。本领域技术人员针对犊牛的胃肠道疾病,尤其是犊牛腹泻做了大量的研究,例如专利CN201410028836.2公开了一种治疗牦牛犊牛腹泻的藏药组合物,其原料组分如下:按重量份计,卷丝苦苣苔375~420份、黄柏320~350份、石榴皮145~160份、山柰100份。该药物组合物具有临床疗效明显、副作用低、无残留、成本低廉、使用方便等特点,对于牦牛犊牛腹泻具有良好的治疗效果。同时,由于采用了中药组合物的形式,在治疗该病中,可有效降低或减少抗生素、化学合成药物在治疗牦牛犊牛腹泻中的使用量,消除药物残留对食品安全和公共卫生的威胁,符合提供安全、无污染动物源食品和人类健康的社会需求。但其并没有详细研究药物的抑菌、镇痛、抗炎等效果。针对上述技术问题,本发明提供了一种治疗犊牛胃肠道疾病的藏药复方。本发明的藏药复方既能快速止泻,又能减少抗生素的使用,降低细菌耐药性的产生。
发明内容
本发明的目的在于通过大量实验研究,提供一种用于治疗犊牛腹泻的藏药复方及其制备方法。具体技术方案如下:
一种用于治疗犊牛胃肠道疾病的藏药复方,所述的藏药复方由下述重量配比的原料制成:三颗针1~3份、沙棘1~4份、诃子5份、甘青青兰2份、矮紫堇2份。
优选地,所述的藏药复方由下述重量配比的原料制成:三颗针2~3份、沙棘1~4份、诃子5份、甘青青兰2份、矮紫堇2份。
优选地,所述的藏药复方由下述重量配比的原料制成:三颗针2份、沙棘4份、诃子5份、甘青青兰2份、矮紫堇2份。
优选地,所述的藏药复方由下述重量配比的原料制成:三颗针2份、沙棘3份、诃子5份、甘青青兰2份、矮紫堇2份。
优选地,所述的藏药复方加药学上可接受的辅料制备成汤剂、片剂、颗粒、丸剂或口服液。
优选地,所述藏药复方制备为口服液。
一种藏药复方口服液的制备方法,包括如下步骤:
(1)取三颗针、沙棘、诃子、甘青青兰、矮紫堇,按照比例称重,冷水清洗去浮尘;
(2)将步骤(1)所取药材,冷水浸泡;
(3)在密闭煎药机中,加入步骤(2)浸泡好的药材,加入5-10倍体积水,115℃,水煎2小时;
(4)收集步骤(3)水煎好的药液,四层纱布过滤得滤液;
(5)再加入5-10倍水,重复步骤(3),115℃,水煎2小时;
(6)收集步骤(5)水煎好的药液,四层纱布过滤得滤液;
(7)合并步骤(4)和步骤(6)的两次滤液,加入旋转蒸发仪,0.05Mpa,60℃,进行药液的浓缩,浓缩至1毫升药液等于1克原药材;
(8)在步骤(7)浓缩的药液中加入0.2%山梨酸钾,装罐封口。
所述的藏药复方在制备治疗犊牛胃肠道疾病药物中的应用。
所述的藏药复方在制备治疗犊牛结肠炎药物中的应用。
所述的藏药复方在制备治疗犊牛腹泻药物中的应用。
与现有技术相比,本发明涉及的治疗犊牛腹泻的藏药复方具有如下优点和显著的进步:
(1)使用非常方便,水煎剂,便于动物灌服、拌饲和饮水给药,也容易被肠粘膜吸收,还具备抑制或杀死导致感染的大肠杆菌病原菌的作用,抑制肠上皮细胞脱落,降低粘膜水肿、减少炎症细胞浸润,促进腹泻快速愈合,不易产生细菌耐药性,不影响动物生产性能。
(2)止血镇痛功效,同时还具备活化细胞、修复受损细胞的作用,促进组织、细胞的修复与再生。
(3)不含刺激类、麻醉类和激素类物质,产品绿色安全,且所含的五种物质能发挥止泻、涩肠、消炎的协同作用,对犊牛腹泻可发挥高效治疗作用。
附图说明
图1藏药复方对DSS诱导小鼠结肠炎的体重影响
图2藏药复方对DSS诱导小鼠结肠炎疾病活动指数的影响
图3小鼠结肠组织中MPO含量变化
图4小鼠结肠组中MDA含量变化
图5小鼠结肠组织中SOD含量变化
图6小鼠结肠组织中GSH含量变化
具体实施方式
以下结合具体实施例对本发明的保护范围进行详细说明,但应当指出的是,本发明的保护范围并不限于以下实施例,同时保护藏药复方在制备治疗犊牛腹泻药物中的应用,包括不同剂型、剂量、联合用药等。凡本领域技术人员按照本发明的思路在现有技术上通过逻辑分析、推断和实验得出的技术方案,均属于本发明所请求保护的范围。
应理解,上述简述和下文的详述为示例性且仅用于解释,而不对本文发明主题做任何限制。在本申请中,必须注意,除非文中另有清楚的说明,否则在本说明书和权利要求书中所用的单数形式包括所指事物的复数形式。还应注意,除非另有说明,否则所用“或”、“或者”表示“和/或”。此外,所用术语“包括”以及其他形式,例如“包含”、“含”和“含有”并非限制性。
以下实施例所述的牛津杯(Oxford Cup)法是抗生素效价测定的一种方法,通常可以分为二剂量法和三剂量法。其具体操作方法是:将已灭菌的琼脂培养基加热到完全融化,倒在培养皿内,每皿15ml(下层),待其凝固。此外,将融化的PDA培养基冷却到50℃左右混入试验菌,将混有菌的培养基5ml加到已凝固的培养基上待凝固(上层)。以无菌操作在培养基表面直接垂直放上牛津杯(内径6mm、外径8mm、高10mm的圆形小管,管的两端要光滑,也可用玻璃管、瓷管),轻轻加压,使其与培养基接触无空隙,在杯中加入待检样品(发酵液),牛津杯一般可以装240微升,勿使其外溢。加满后置37℃培养16-18小时,观察结果,抑菌圈用尺直接量就可以。在培养中,一方面试验菌开始生长,另一方面抗生素呈球面扩散,离杯越近,抗生素浓度越大,离杯越远抗生素浓度越小。随着抗生素浓度减小,有一条最低抑菌浓度带,在带范围内,菌不能生长,而呈透明的圆圈,这就叫“抑菌圈”。抗生素浓度越高,抑菌圈越大。
所述胃肠道疾病包括所有由胃和十二指肠的粘膜损伤引起的胃肠道疾病。胃肠道疾病可由诸如酒精、吸烟、压力、药物及其组合的多种因素引起,但不限与此。导致胃肠道疾病的药物的代表为非甾体抗炎药、类固醇等,但不限与此。非甾体抗炎药的代表为吲哚美辛、双氯芬酸、阿司匹林、对乙酰氨基酚、布洛芬、美洛昔康、萘普生等。
实施例1-5:
本发明提供的用于治疗犊牛腹泻的藏药复方的制备:
藏药复方配方如表1所示,表1中数据为质量比。
表1不同配比的藏药复方
藏药复方口服液的制备方法:
(1)取三颗针、沙棘、诃子、甘青青兰、矮紫堇,按照比例称重,冷水清洗去浮尘;
(2)将步骤(1)取得的药材冷水浸泡24小时;
(3)在密闭煎药机中,加入步骤(2)浸泡好的药材,加入5-10倍体积水,115℃,水煎2小时;
(4)收集步骤(3)水煎好的药液,四层纱布过滤得滤液;
(5)药渣中再加入5-10倍水,重复步骤(3),115℃,水煎2小时;
(6)收集步骤(5)水煎好的药液,四层纱布过滤得滤液;
(7)合并步骤(4)和步骤(6)的两次滤液,加入旋转蒸发仪,0.05Mpa,60℃,进行药液的浓缩,浓缩至1毫升药液等于1克原药材;
(8)加入0.2%山梨酸钾,装罐封口。
对比实施例:
处方组成:诃子5份、甘青青兰2份、矮紫堇2份,其余为水。
制备工艺:诃子、甘青青兰、矮紫堇按照比例称重,冷水清洗去浮尘,冷水浸泡24小时,在密闭煎药机中,加入5-10倍体积水,115℃,水煎2小时,四层纱布过滤的滤液,药渣中再加入5-10倍水,115℃,水煎2小时,四层纱布过滤得滤液,合并两次药液,加入旋转蒸发仪,0.05Mpa,60℃,进行药液的浓缩,浓缩至1毫升药液等于1克原药材,加入0.2%山梨酸钾,装罐封口。
实施例6、藏药复方的止泻镇痛抑菌效果研究
1.抑菌效果研究
取实施例1按照三颗针200克、沙棘300克、诃子500克、甘青青兰200克、矮紫堇200克,实施例2按照三颗针300克、沙棘30克、诃子500克、甘青青兰200克、矮紫堇200克,实施例3按照三颗针200克、沙棘400克、诃子500克、甘青青兰200克、矮紫堇200克,实施例4按照三颗针100克、沙棘300克、诃子500克、甘青青兰200克、矮紫堇200克,实施例5按照三颗针300克、沙棘100克、诃子500克、甘青青兰200克、矮紫堇200克,制备得到的藏药复方口服液,通过牛津杯法对从腹泻犊牛中分离出的高耐药大肠杆菌进行抑菌试验,将高压灭菌后冷却至50℃的MH琼脂培养基倒入直径9mm的一次性塑料培养基,待培养基在紫外灯照射下凝固后,封封口膜置4℃冰箱,备用。将大肠杆菌分离菌株接种于普通营养肉汤,37℃过夜孵育12-16h;使用细菌比浊仪调整营养肉汤培养物至0.5麦氏比浊度。使用灭菌棉签将稀释好的菌液均匀涂布在MH培养基上,保证菌液涂布均匀。在涂布菌液的MH琼脂培养基表面放入4个轻轻加热的灭菌牛津杯(内经6±0.1mm,外径8±0.1mm,高10±0.1mm),使其与培养基无缝隙接触,将制备好的藏药复方口服液稀释成8个梯度浓度分别为2000mg/mL、1000mg/mL、500mg/mL、250mg/mL、125mg/mL、64mg/mL、32mg/mL、16mg/mL,浓度由高到低依次编号为1-8,用牛津杯法进行对大肠杆菌抑菌试验。浓度由高到低分别编号1-8,每个牛津杯中加300μL溶液,37℃培养18-24h。游标卡尺测定抑菌圈的大小,重复3次计算其平均值。抑菌直径<10mm为不敏感;10mm≤抑菌圈直径<15mm为轻度敏感,15≤抑菌直径<20mm为中度敏感;抑菌直径>20mm为高度敏感。实验结果如表2所示,藏药复方对大肠杆菌具有显著的抑菌作用,在浓度为1000mg/mL、500mg/mL、250mg/mL条件下,大肠杆菌对实施例1、实施例3敏感情况相同,分别为中度敏感、中度敏感、轻度敏感,大肠杆菌对实施例5敏感情况分别为中度敏感、轻度敏感、轻度敏感。实施例2、实施例4对大肠杆菌的抑菌浓度过大,因此在动物试验中淘汰。藏药复方实施例1、实施例3、实施例5可以不同程度的抑制大肠杆菌。
表2不同配方在不同浓度下对大肠杆菌的抑菌圈直径
2.镇痛效果研究
本实验采用藏兽药复方药效学试验——醋酸致小鼠扭体试验来研究藏药复方对小鼠的镇痛效果,取实施例1按照三颗针200克、沙棘300克、诃子500克、甘青青兰200克、矮紫堇200克,实施例3按照三颗针200克、沙棘400克、诃子500克、甘青青兰200克、矮紫堇200克,实施例5按照三颗针300克、沙棘100克、诃子500克、甘青青兰200克、矮紫堇200克,制备得到的藏药。BALB/c小鼠50只,体重为(20±2)g,雌雄各半,随机分为5组,每组10只。第一组为模型组,第二组为吲哚美辛阳性对照组(3mg/kg·bw),第三组为实施例1(2mL/kg·bw)、第四组为实施例3(2mL/kg·bw)、第五组为实施例5(2mL/kg·bw)。模型组小鼠,灌胃给予生理盐水,0.4m L/只;阳性对照组小鼠灌胃给予3mg/kg的吲哚美辛;各组小鼠灌胃给药1h后,每只小鼠腹腔注射0.6%冰醋酸溶液0.2m L,观察并记录在注射冰醋酸后小鼠的扭体的潜伏期及30min内的扭体次数并计算扭体反应抑制率。
抑制率=(模型组扭体次数-试验组扭体次数)/模型组扭体次数×100%
由表3可知,实施例1、3、5试验组均能明显抑制因腹腔注射冰醋酸引起的扭体次数,且实施例1、3试验组与阳性对照组抑制率相当,说明实施例1、3具有明显的外周镇痛作用。
表3不同组别小鼠的扭体次数与抑制率比较
对不同时间点的小鼠痛阈值进行检测,具体结果见表4,阳性对照组、实施例1、3、5试验组小鼠在30、60、90min时间点的痛阈值同模型组小鼠的痛阈值比较,差异不显著(P>0.05)。在120min,阳性对照组、实施例1、3、5试验组小鼠的痛阈值同模型组小鼠的痛阈值比较,差异显著(P<0.05)。说明实施例1、3、5具有一定的中枢镇痛作用。
表4不同时间点的痛阈值比较
3.抗炎效果研究
取实施例1按照三颗针200克、沙棘300克、诃子500克、甘青青兰200克、矮紫堇200克,实施例3按照三颗针200克、沙棘400克、诃子500克、甘青青兰200克、矮紫堇200克,实施例5按照三颗针300克、沙棘100克、诃子500克、甘青青兰200克、矮紫堇200克,制备得到的藏药口服液。BALB/c小鼠50只,体重为(20±2)g,雌雄各半,随机分为5组,每组10只。第一组为模型组,第二组为吲哚美辛阳性对照组(3mg/kg·bw),第三组为实施例1(2mL/kg·bw)、第四组为实施例3(2mL/kg·bw)、第五组为实施例5(2mL/kg·bw)。模型组小鼠给予生理盐水,0.4m L/只;小鼠提前连续5天给药,每天灌胃1次,末次给药1h后,取0.03m L二甲苯均匀涂在小鼠右耳前后两面,左耳作对照。1h后将小鼠脱颈处死,用直径8mm打孔器沿耳廓基线两耳相同部位打下两圆耳片,称重,计算肿胀抑制率。
肿胀度=右耳重-左耳重;肿胀率=肿胀度/左耳重×100%
肿胀抑制率=(模型组肿胀度-给药组肿胀度)/模型组肿胀度×100%
二甲苯致小鼠耳肿胀试验结果表明(如表5),实施例1、3、5对二甲苯所导致的小鼠耳肿胀均有一定的抑制效果。实施例1小鼠的肿胀率为54.90%,抑制率为30.66%,同模型组小鼠肿胀率比较,差异极显著(P<0.01);实施例3鼠肿胀率为56.33%、抑制率为30.0%,同模型组比较,差异显著(P<0.05)。
表5不同组小鼠的耳肿胀率比较
4.肠推进实验
取实施例1按照三颗针200克、沙棘300克、诃子500克、甘青青兰200克、矮紫堇200克,实施例3按照三颗针200克、沙棘400克、诃子500克、甘青青兰200克、矮紫堇200克,实施例5按照三颗针300克、沙棘100克、诃子500克、甘青青兰200克、矮紫堇200克,制备得到的藏药口服液。BALB/c小鼠50只,体重为(20±2)g,雌雄各半,随机分为5组,每组10只。第一组为模型组,第二组为复方地芬诺酯阳性对照组(3mg/kg·bw),第三组为实施例1(2mL/kg·bw)、第四组为实施例3(2mL/kg·bw)、第五组为实施例5(2mL/kg·bw)。模型组小鼠灌胃给予生理盐水,0.4m L/只;阳性对照组、实施例1、3、5组小鼠按给药剂量每天灌胃一次,连续给药5天。末次给药前禁食不禁水12h,末次给药1h后,将5.0%炭末混悬液按0.15m L/只给小鼠灌胃,灌胃给药30min后,颈部脱臼处死,打开腹腔分离肠系膜,剪取上端至幽门,下端至回盲部的肠管,置于托盘上。轻轻将肠管摆成直线,测量肠管长度作为“小肠总长度”。从幽门至墨汁前沿的距离作为“墨汁在肠管内推进距离”。通过公式计算墨汁推进百分率,并注意观察各组小肠容积是否增大。
炭末推进百分率(%)=炭末前段到幽门的距离/小肠全长×100%
碳墨推进试验结果表明(如表6),实施例5小鼠的肠推进率为62.82%,同模型组小鼠肠推进率比较,肠推进率显著降低(P<0.05);实施例1、3和阳性对照组小鼠的肠推进率与模型组比较,可以极显著降低小鼠的肠推进率(P<0.01)。结果表明,实施例1、3能够显著地降低碳墨推进,具有一定的止泻功能,效果与复方地芬诺酯相似。
表6不同组小鼠的肠推进效果比较
5.番泻叶致泻试验
取实施例1按照三颗针200克、沙棘300克、诃子500克、甘青青兰200克、矮紫堇200克,实施例3按照三颗针200克、沙棘400克、诃子500克、甘青青兰200克、矮紫堇200克,实施例5按照三颗针300克、沙棘100克、诃子500克、甘青青兰200克、矮紫堇200克,制备得到的藏药口服液。BALB/c小鼠50只,体重为(20±2)g,雌雄各半,随机分为5组,每组10只。第一组为模型组,第二组为复方地芬诺酯阳性对照组(3mg/kg·bw),第三组为实施例1(2mL/kg·bw)、第四组为实施例3(2mL/kg·bw)、第五组为实施例5(2mL/kg·bw)。模型组小鼠灌胃给予生理盐水,0.4m L/只;阳性对照组、实施例1、3、5组小鼠按给药剂量每天灌胃一次,连续给药5天。末次给药前禁食不禁水12小时,末次给药0.5h后,灌胃浓度为1g/m L番泻叶,0.4mL/只。每只小鼠单笼观察,每笼下铺至吸水滤纸,每隔2小时换一次滤纸,分别计算小鼠在2、4、6h的腹泻指数。
腹泻指数=稀便率×稀便级×100%
结果表明,给予番泻叶后模型组小鼠的腹泻现象明显增强,实施例1能够在2-4h内极显著地降低番泻叶造成的腹泻,复方地芬诺酯组小鼠腹泻指数1.83,同模型组比较差异显著(P<0.05),实施例1小鼠的腹泻指数1.75,同模型组比较,差异极显著(P<0.01)。
表7不同组小鼠的腹泻指数比较
6.藏药复方对溃疡性结肠炎的治疗效果
取实施例1按照三颗针200克、沙棘300克、诃子500克、甘青青兰200克、矮紫堇200克,实施例3按照三颗针200克、沙棘400克、诃子500克、甘青青兰200克、矮紫堇200克,实施例5按照三颗针300克、沙棘100克、诃子500克、甘青青兰200克、矮紫堇200克,制备得到的藏药口服液。取SPF级BALB/c小鼠50只,随机分为5组,每组10只,适应性喂养一周用于试验。分别为正常对照组、模型组、柳氮磺胺吡啶阳性对照组、复方1、2、3组。用药组小鼠提前给药3d,每天按照柳氮磺胺吡啶阳性对照组(2mg/kg·bw)、实施例1(2mL/kg·bw)、实施例3(2mL/kg·bw)、实施例5(2mL/kg·bw);模型组和对照组小鼠每天给予相同体积的蒸馏水。除正常对照组外,每组小鼠均自由饮用浓度为3.5%的DSS水,连续饮用6d。每天观察小鼠的粪便性状,进行便潜血检测,对小鼠进行称重。试验结束,分离结肠,冻于-80℃。
藏药复方对小鼠溃疡性结肠炎模型的治疗结果表明,DSS诱发的模型组小鼠在试验的第2d,体重开始减轻,精神萎靡;在试验的第3d开始出现软便、腹泻的现象,便潜血检测为蓝色;试验第4d小鼠活动减少,蜷缩在鼠笼,嗜睡,开始出现血便,体重下降明显,疾病活动指数显著升高(P<0.01);第3d,小鼠全部出现血便,体重同正常对照组小鼠差异极显著(P<0.01),疾病活动指数升高极显著(P<0.01)。实施例3干预组小鼠,小鼠精神活动良好,个别小鼠出现软便、腹泻现象,均无血便出现,体重略有增加,从试验第4d小鼠DAI评分极显著低于模型组(P<0.01)。实施例1干预组小鼠,小鼠体重略有下降,试验第4d小鼠体重下降同正常对照组小鼠差异极显著(P<0.01),精神活动不佳,出现腹泻,试验第5d DAI评分与模型组相比差异极显著(P<0.01),第6d差异显著(P<0.05)。而采用实施例5干预小鼠,小鼠体重下降明显,与模型组相比稍有好转,但差异不显著(P>0.05)。由此可见,实施例3对小鼠结肠炎的治疗效果最佳(如图1,2)。
结肠组织中髓过氧化物酶(MPO)检测结果表明(见图3),同正常对照组比较,模型组小鼠的结肠组织中MPO活力显著升高(P<0.01);给药组小鼠结肠组织中MPO活力同模型组比较明显降低,实施例1、3的MPO活性下降同模型组比较,差异极显著(P<0.01);实施例5与模型组比较,差异显著(P<0.05);说明实施例1、3、5具有降低结肠炎组织中MPO活力的作用。
丙二醛(MDA)含量、超氧化物岐化酶(SOD)活力、谷胱甘肽过氧化物酶(GSH-Px)活性的测定结果表明,同正常对照组相比,模型组小鼠结肠组织中MDA的含量极显著升高(P<0.01)。与模型组比较,实施例1、5可显著的降低结肠组织中MDA的含量(P<0.01)(见图4);说明实施例1、5具有降低结肠炎组织中MDA含量至正常水平的作用。DSS诱导的小鼠结肠炎模型中,结肠组织中SOD、GSH的活力降低。与模型组相比,实施例3小鼠结肠组织中SOD、GSH的活力升高,差异极显著(P<0.01),阳性对照组、实施例5组差异显著(P<0.05)(见图5,6),说明实施例1、3具有升高结肠炎组织中SOD、GSH活力的作用。
通过以上大量实验验证得出,本发明的治疗犊牛腹泻的藏药复方具有如下优点:
(1)具有止泻、涩肠的功效。本发明的藏药复方主要由三颗针、沙棘、诃子、甘青青兰和矮紫堇组成。三颗针具有清热燥湿,泻火解毒功效;沙棘具有消食化滞,活血散瘀功效;诃子具有涩肠止泻、敛肺止咳功效;甘青青兰具有和胃疏肝,清热利水功效;矮紫堇具有清热消炎功效。藏药复方极显著降低小鼠的肠推进率,并且显著降低腹泻指数,不影响动物生产性能。
(2)能够抗菌消炎。本发明的藏药复方水煎剂对腹泻犊牛高耐药大肠杆菌分离株有很强的抑菌和杀菌作用,不易产生细菌耐药性。
(3)促进腹泻快速愈合,抑制肠上皮细胞脱落,降低粘膜水肿、减少炎症细胞浸润,降低机体过氧化酶的含量,升高超氧化歧化酶的含量,缓解肠道黏膜损伤,保护肠粘膜。
(4)具有明显的外周镇痛和中枢镇痛作用。
Claims (10)
1.一种用于治疗犊牛胃肠道疾病的藏药复方,其特征在于,所述的藏药复方由下述重量配比的原料制成:三颗针1~3份、沙棘1~4份、诃子5份、甘青青兰2份、矮紫堇2份。
2.根据权利要求1所述的藏药复方,其特征在于,所述的藏药复方由下述重量配比的原料制成:三颗针2~3份、沙棘1~4份、诃子5份、甘青青兰2份、矮紫堇2份。
3.根据权利要求2所述的藏药复方,其特征在于,所述的藏药复方由下述重量配比的原料制成:三颗针2份、沙棘4份、诃子5份、甘青青兰2份、矮紫堇2份。
4.根据权利要求2所述的藏药复方,其特征在于,所述的藏药复方由下述重量配比的原料制成:三颗针2份、沙棘3份、诃子5份、甘青青兰2份、矮紫堇2份。
5.如权利要求1-4任一项所述的藏药复方,其特征在于,所述的藏药复方加药学上可接受的辅料制备成汤剂、片剂、颗粒、丸剂或口服液。
6.根据权利要求5所述的藏药复方,其特征在于,所述藏药复方加药学上可接受的辅料制备成口服液。
7.一种如权利要求1-4任一项所述的藏药复方的口服液的制备方法,其特征在于,包括如下步骤:
(1)取三颗针、沙棘、诃子、甘青青兰、矮紫堇,按照比例称重,冷水清洗去浮尘;
(2)将步骤(1)所取药材,冷水浸泡;
(3)在密闭煎药机中,加入步骤(2)浸泡好的药材,加入5-10倍体积水,115℃,水煎2小时;
(4)收集步骤(3)水煎好的药液,四层纱布过滤得滤液;
(5)再加入5-10倍水,重复步骤(3),115℃,水煎2小时;
(6)收集步骤(5)水煎好的药液,四层纱布过滤得滤液;
(7)合并步骤(4)和步骤(6)的两次滤液,加入旋转蒸发仪,0.05Mpa,60℃,进行药液的浓缩,浓缩至1毫升药液等于1克原药材;
(8)在步骤(7)浓缩的药液中加入0.2%山梨酸钾,装罐封口。
8.如权利要求1-4任一项所述的藏药复方在制备治疗犊牛胃肠道疾病药物中的应用。
9.如权利要求1-4任一项所述的藏药复方在制备治疗犊牛结肠炎药物中的应用。
10.如权利要求1-4任一项所述的藏药复方在制备治疗犊牛腹泻药物中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110042083.0A CN112603942B (zh) | 2021-01-13 | 2021-01-13 | 一种用于治疗犊牛胃肠道疾病的藏药复方及其制备方法和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110042083.0A CN112603942B (zh) | 2021-01-13 | 2021-01-13 | 一种用于治疗犊牛胃肠道疾病的藏药复方及其制备方法和应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN112603942A true CN112603942A (zh) | 2021-04-06 |
CN112603942B CN112603942B (zh) | 2022-09-02 |
Family
ID=75253976
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110042083.0A Expired - Fee Related CN112603942B (zh) | 2021-01-13 | 2021-01-13 | 一种用于治疗犊牛胃肠道疾病的藏药复方及其制备方法和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN112603942B (zh) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105055576A (zh) * | 2015-09-02 | 2015-11-18 | 东北农业大学 | 一种预防和治疗畜禽大肠杆菌病的复方中药及其制备方法 |
CN106955296A (zh) * | 2016-01-11 | 2017-07-18 | 天津嘉创生物科技有限公司 | 治疗犊牛腹泻的中药组合物及其制备方法 |
-
2021
- 2021-01-13 CN CN202110042083.0A patent/CN112603942B/zh not_active Expired - Fee Related
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105055576A (zh) * | 2015-09-02 | 2015-11-18 | 东北农业大学 | 一种预防和治疗畜禽大肠杆菌病的复方中药及其制备方法 |
CN106955296A (zh) * | 2016-01-11 | 2017-07-18 | 天津嘉创生物科技有限公司 | 治疗犊牛腹泻的中药组合物及其制备方法 |
Non-Patent Citations (2)
Title |
---|
才让措等: "藏药"智托洁白丸"功能主治及方解浅述", 《中国民族民间医药》 * |
王丹阳等: "诃子、矮紫堇、甘青乌头提取物对牛病毒性腹泻病毒的体外抑制作用", 《畜牧兽医学报》 * |
Also Published As
Publication number | Publication date |
---|---|
CN112603942B (zh) | 2022-09-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101632754B (zh) | 一种治疗咽炎的中药组合物及其制备方法 | |
CN112603942B (zh) | 一种用于治疗犊牛胃肠道疾病的藏药复方及其制备方法和应用 | |
CN112618600B (zh) | 一种用于治疗犊牛胃肠道疾病药物的藏药复方及其制备方法 | |
CN110538281A (zh) | 用于治疗咽炎、扁桃体炎的中药制剂、制备方法及应用 | |
CN101049345B (zh) | 一种治疗口腔和咽喉疾病的制剂及其制备方法 | |
CN101036732B (zh) | 治疗食道癌的中药制剂及其配制方法 | |
CN109157574A (zh) | 一种用于危重患者口腔护理的中药组合物及含其口腔护理液 | |
CN113648302A (zh) | 用于治疗前列腺炎或前列腺增生的药物 | |
CN102727804B (zh) | 一种治疗脓疮、疖子的中药组合物及其制备方法 | |
CN109125427B (zh) | 一种盆炎净栓剂及其制备方法 | |
CN117018151B (zh) | 一种治疗小儿风寒咳嗽的中药组合物及其应用 | |
CN115569165B (zh) | 中药组合物在制备治疗细菌性前列腺炎的药物中的应用 | |
CN116173129B (zh) | 一种治疗急性痛风性关节炎外用中药膏及制备方法 | |
CN107362267A (zh) | 一种用于治疗毒蛇咬伤的中药制剂 | |
Siboulet et al. | A New “One-Minute” Treatment of Gonorrhoea | |
CN100409884C (zh) | 一种治疗感冒的中药 | |
CN1088378C (zh) | 治疗慢性浅表性胃炎的中药口服液及其制备方法 | |
CN104906379A (zh) | 一种治疗大疱性脓包疮的中药软膏及其制备方法 | |
CN111329879A (zh) | 根治良性肿瘤的白降丹及其使用方法 | |
CN117883530A (zh) | 一种治疗动物腹泻的中药组合物及其制备方法 | |
CN111956777A (zh) | 一种快速退热的中药及其制备方法 | |
CN115025182A (zh) | 一种治疗呼吸道病毒感染的中药制剂 | |
CN117045757A (zh) | 一种调理新陈代谢阻碍、降低尿酸浓度的组合物及其制备方法 | |
CN116570641A (zh) | 沙蒿籽用于制备治疗猪口腔烫伤引起流涎的药物的应用 | |
CN113750082A (zh) | 用于治疗前列腺炎及前列腺增生的药物及应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20220902 |